An observational study in Degenerative Conditions, Neurologic, sponsored by SeaSpine, Inc.. Status unknown at 2 sites in United States. Per ClinicalTrials.gov, last updated 2023-04-04.
Sponsored by SeaSpine, Inc. (part of Orthofix Inc.) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 176 studies in Neurodegenerative Diseases with a site in United States — 45 open to participants now, 58 under way, 4 of them phase 3. Neurodegenerative Diseases · United States.
Among the 176 studies in Neurodegenerative Diseases with a site in United States, this one is the 33rd largest by enrollment of the 54 observational ones that give a count, is one of 10 that started in 2020, is one of 54 observational ones, and was the 94th registered.
436 studies on the registry are indexed under Neurodegenerative Diseases; 143 are open to participants now.
Browse Neurodegenerative Diseases studies →45 of the 176 studies in Neurodegenerative Diseases with a site in United States are open now. Recruiting first, the newest first:
Vima Therapeutics · Sites in United States, Canada
Ages 18–65
The University of Texas Medical Branch, Galveston · Sites in United States
Ages 18+ · Women only · Healthy volunteers
Eli Lilly and Company · Sites in United States, Australia, New Zealand and 1 more country
Ages 50–85
Eli Lilly and Company · Sites in United States, Japan, Korea, Republic of and 1 more country
Ages 55–85
Longevity Metrics, Inc. · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 101 Neurodegenerative Diseases studies recruiting now, 52 (51%) set no upper age limit and 11 (11%) stop at 75 or younger; 20 take children under 18; 49 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
176 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 45 · Phase 3 24 · Phase 4 1
First in 1993; this study’s year is marked. 10 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 50 is below the median of 186 across 156 observational studies indexed under Neurodegenerative Diseases.
Median enrollment 63 across the 120 interventional studies, 85 across the 54 observational. Of the 104 that completed or were terminated, 33 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
80 of 176 have an industry lead sponsor. The 10 most frequent:
This study is registered under SeaSpine, Inc., one of the names counted as Orthofix Inc.. Under that name alone:
SeaSpine, Inc. is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
Orthofix Inc. has 1 study filed under Neurodegenerative Diseases — fewer than ten, so there is no comparison to draw.
18 of the studies in Neurodegenerative Diseases with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04838301University of ArizonaAllopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease | 2026-11-18 |
| NCT06268886Bristol-Myers SquibbStudy to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease | 2026-12-17 |
| NCT02414178Washington University School of MedicineF 18 T807 Tau PET Imaging in Dominantly Inherited Alzheimer's Network (DIAN Project) | 2027-01 |
| NCT06185764Vertex Pharmaceuticals IncorporatedA Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) | 2027-02-02 |
| NCT02553525Duke UniversityEffects of Stimulation Patterns of Deep Brain Stimulation | 2027-03 |
Add all 18 to your calendar (.ics) → With an account.
Among the 176 studies in Neurodegenerative Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To perform a clinical evaluation of safety and performance for the SeaSpine Non- Cervical Pedicle Screw Systems
A multi-center, post-market, clinical evaluation for subjects implanted with the SeaSpine Non-Cervical Pedicle Screw Systems
Patients who have been implanted with a SeaSpine Non-Cervical Pedicle Screw System
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
50 patients who have been implanted with SeaSpine Non-Cervical Pedicle Screw Systems
Device: SeaSpine Non-Cervical Pedicle Screw Systems
Any patient treated with a SeaSpine Non-Cervical Pedicle Screw System
The primary outcome for the study is device performance.
Device performance is defined as lack of component failure involving screw and/or rod fracture and/or screw loosening or disassociation.
Time frame: 12 months post-operative
Evaluation of unanticipated adverse device effects (UADE)
Intra or Post-Procedure UADEs
Time frame: 12-months
Ran from Mar 2020 to primary completion in Jun 2021, 15 months.
Of 82 observational studies under Neurodegenerative Diseases, half reached primary completion within 94 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 216. This study's 15 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.